Sera Prognostics vs YD Bio
SERA and YDES side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SERA and YDES compare
YD Bio grew revenue faster over the last twelve months (16.9% versus 1.1% for Sera Prognostics).
YD Bio keeps more of each dollar of sales as profit, with a net margin of −1393% compared with −34867% at Sera Prognostics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SERA | YDES |
|---|---|---|
| Size and price | ||
| Market cap | $76.5M | – |
| Share price | $1.94 | $6.15 |
| Change, 1 year | −23.9% | −29.1% |
| Change, 5 years | −82.0% | −39.5% |
| Beta (5Y) | 1.23 | 0.14 |
| Employees | – | 13 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 797× | – |
| P/B | 1.5× | – |
| FCF yield | −37.9% | – |
| Growth | ||
| Revenue growth (TTM) | 1.1% | 16.9% (better) |
| Revenue growth, 5Y average | 26.5% | – |
| Profitability | ||
| Gross margin | – | 28.1% |
| Operating margin | −38755% | −883% (better) |
| Net margin | −34867% | −1393% (better) |
| FCF margin | −30199% | −1347% (better) |
| Return on equity | −49.7% (better) | −174% |
| Return on invested capital | −124% (better) | −130% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −5315.0× | – |
| Current ratio | 1.88 | 5.23 (better) |
| Altman Z-score | −5.45 | – |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 43.2% | – |
| Held by insiders | 30.4% | 92.8% |
| Insider net buying, 12 months | −$524K | $129K (better) |
| Short interest, % of float | 0.80% | – |
Go deeper
- SERA stock overview
- SERA income statement
- SERA valuation and score
- YDES stock overview
- YDES income statement
- YDES valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.